Muscle Function
Conditions
Keywords
Muscle function, L-Carnitine, Carnipure, DXA, anabolism, 6 minute walk, dynamometry, muscle biopsy
Brief summary
This study evaluates two L-Carnitine-based products on muscle function in healthy older adults (55 to 70 years old). These products are suspected to improve muscle function and possibly promote building of muscle mass. One third of the subjects will be on Carnipure Product 1, one third will be on Carnipure Product 2 and one third will be on placebo.
Interventions
DIETARY_SUPPLEMENTCarnipure Product 1
DIETARY_SUPPLEMENTCarnipure Product 2
OTHERPlacebo
Placebo
Sponsors
Lonza Inc.
KGK Science Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male or female adults, aged 55 to 70 years * BMI of 21 kg/m2 to 33 kg/m2 * Subjects in good physical condition such that they can perform exercise testing safely, as determined by the Qualified Investigator based on medical history, physical examination, electrocardiogram and laboratory results * Subjects who are sedentary and not currently engaging in any regular exercise. * Subjects who agree to maintain their current level of activity and current dietary habits throughout the trial period. * Subjects who have given voluntary, written, informed consent to participate in the study.
Exclusion criteria
* Subjects who are smokers or have been a smoker within the past 1 year from screening. * Subjects who are pregnant or breastfeeding * Subjects who have experienced weight loss or gain of greater than 4.5 kg (approximately 10 lbs) within 3 months of randomization * Subjects diagnosed with active heart disease * Subjects with uncontrolled hypertension (≥ 140 mmHg) * Subjects with renal or hepatic impairment or disease * Subjects with any major diseases of the gastrointestinal, pulmonary or endocrine systems * Subjects with a history of seizures * Subjects with Type I or Type II Diabetes * Subjects with active cancer (excluding basal cell carcinoma) * Subjects with neurological or significant psychiatric illnesses, including Parkinson's disease and bi-polar disorder * Subjects with unstable thyroid disease * Subjects who are immuno-compromised (HIV positive, on anti-rejection medication, rheumatoid arthritis) * Subjects with metal fixation plates or screws from a previous surgery * Subjects who are taking oral anticoagulants (blood thinners) such as warfarin (Coumadin) or Dabigatran (Pradaxa) or antiplatelet agents such as Clopidogrel (Plavix) * Subjects who are regularly taking NSAID medications such as aspirin, must stop at least one week prior to the micro-needle muscle biopsy procedures. * Subjects with a known allergy to anesthetic * Subjects who currently experience any medical condition that interferes with the ability to undergo physical strength testing during the study * Subjects currently taking NHPs must have been using their current dosing regimen for at least one month prior to baseline and must maintain their current dosing regimen throughout the trial and must not begin taking any new NHPs throughout the trial. If the subject wishes to stop taking the NHP prior to beginning the trial, they must do so at least 1 week prior to randomization. * Subjects who use illicit drugs or have a history of alcohol or drug abuse within the past 6 months * Subjects who currently consume greater than 2 standard alcoholic drinks per day. * Subjects who have participated in a clinical research trial within 30 days prior to randomization. * Subjects with an allergy or sensitivity to the investigational product ingredient. * Subjects who are cognitively impaired and/or who are unable to give informed consent * Subjects who have abnormal laboratory results or any other medical or psychological condition which, in the opinion of the Qualified Investigator, may adversely affect the subjects ability to complete the study or its measures or which may pose significant risk to the subject.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in Muscle Function Composite Endpoint from Baseline to Day 57 of subjects administer Carnipure Product 2 versus those administered Placebo | Baseline and Day 57 | A composite endpoint determined by multiplying the values of Lean Body Mass (as assessed by DXA, kg), and functional muscle strength (as assessed by 6 Minute Walk Test, metres; Lower Body Dynamometry, kg; Upper Body Dynamometry, kg). Percent change from baseline to day 57 will be derived. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo | Baseline and Day 57 | Functional lower body strength will be determined using a hand-held dynamometer to measure leg extension resistance (kg of resistance). |
| Changes in functional upper body strength from baseline to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo | Baseline and Day 57 | Functional upper body strength will be determined using a grip strength dynamometer to measure grip strength resistance (kg of resistance). |
| Changes in Quality of Life questionnaire score from baseline to day 57 in subjects administered Carnipure Product 2 versus those administered Placebo | Baseline and Day 57 | Assessed using the RAND SF-36 questionnaire |
| Changes in Lean Body Mass from baseline to day 57 in subjects administered Carnipure Product 2 versus those administered Placebo | Baseline and Day 57 | Lean Body Mass measured by DXA scan |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo | Baseline to Day 57 | Functional lower body strength will be determined using a hand-held dynamometer to measure leg extension resistance (kg of resistance). |
| Changes in functional lower body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | Baseline and Day 57 | Functional lower body strength will be determined using a hand-held dynamometer to measure leg extension resistance (kg of resistance). |
| Changes in functional upper body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo | Baseline and Day 57 | Functional upper body strength will be determined using a grip strength dynamometer to measure grip strength resistance (kg of resistance). |
| Changes in functional upper body strength from baseline to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | Baseline and Day 57 | Functional upper body strength will be determined using a grip strength dynamometer to measure grip strength resistance (kg of resistance). |
| Changes in Quality of Life questionnaire score from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Placebo | Baseline and Day 57 | Assessed using the RAND SF-36 questionnaire |
| Changes in Quality of Life questionnaire score from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | Baseline and Day 57 | Assessed using the RAND SF-36 questionnaire |
| Changes in muscle metabolism from baseline to day 57 in subjects administered Carnipure Product 1 versus Placebo | Baseline and Day 57 | Assessed by laboratory analysis of muscle biopsy samples collected at baseline (pre-strength testing) and Day 57 (pre and post-strength testing) |
| Changes in muscle metabolism from baseline to day 57 in subjects administered Carnipure Product 1 versus Carnipure Product 2 | Baseline and Day 57 | Assessed by laboratory analysis of muscle biopsy samples collected at baseline (pre-strength testing) and Day 57 (pre and post-strength testing) |
| Changes in muscle metabolism from baseline to day 57 in subjects administered Carnipure Product 2 versus Placebo | Baseline and Day 57 | Assessed by laboratory analysis of muscle biopsy samples collected at baseline (pre-strength testing) and Day 57 (pre and post-strength testing) |
| Changes in vital signs from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Placebo | Screening to Day 57 | Blood pressure, heart rate, BMI, electrocardiogram |
| Changes in vital signs from screening to day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | Screening to Day 57 | Blood pressure, heart rate, BMI, electrocardiogram |
| Changes in hematology and clinical chemistry from screening to Day 57 in subjects administered Carnipure Product 2 versus those administered Placebo | Screening and Day 57 | CBC, electrolytes, glucose, creatinine, AST, ALT, GGT, bilirubin |
| Changes in hematology and clinical chemistry from screening to Day 57 in subjects administered Carnipure Product 1 versus those administered Placebo | Screening and Day 57 | CBC, electrolytes, glucose, creatinine, AST, ALT, GGT, bilirubin |
| Changes in hematology and clinical chemistry from screening to Day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | Screening and Day 57 | CBC, electrolytes, glucose, creatinine, AST, ALT, GGT, bilirubin |
| Number of adverse events experienced in subjects administered Carnipure Product 2 versus those administered Placebo | 57 days | — |
| Number of adverse events experienced in subjects administered Carnipure Product 1 versus those administered Placebo | 57 days | — |
| Number of adverse events experienced in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | 57 days | — |
| Changes in vital signs from baseline to day 57 in subjects administered Carnipure Product 2 versus those administered Placebo | Screening to Day 57 | Blood pressure, heart rate, BMI, electrocardiogram |
| Percent Change in Muscle Function Composite Endpoint from Baseline to Day 57 of subjects administer Carnipure Product 1 versus those administered Placebo | Baseline and Day 57 | A composite endpoint determined by multiplying the values of Lean Body Mass (as assessed by DXA, kg), and functional muscle strength (as assessed by 6 Minute Walk Test, metres; Lower Body Dynamometry, kg; Upper Body Dynamometry, kg). Percent change from baseline to day 57 will be derived. |
| Percent Change in Muscle Function Composite Endpoint from Baseline to Day 57 of subjects administer Carnipure Product 1 versus those administered Carnipure Product 2 | Baseline and Day 57 | A composite endpoint determined by multiplying the values of Lean Body Mass (as assessed by DXA, kg), and functional muscle strength (as assessed by 6 Minute Walk Test, metres; Lower Body Dynamometry, kg; Upper Body Dynamometry, kg). Percent change from baseline to day 57 will be derived. |
| Changes in Lean Body Mass from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Placebo | Baseline and Day 57 | Lean Body Mass measured by DXA scan |
| Changes in Lean Body Mass from baseline to day 57 in subjects administered Carnipure Product 1 versus those administered Carnipure Product 2 | Baseline and Day 57 | Lean Body Mass measured by DXA scan |
Countries
Canada
Outcome results
None listed